Key result
Vildagliptin treatment improved vascular smooth muscle relaxation and reduced senescence and SASP markers in the aorta of doxorubicin-treated rats.
Why the study?
Doxorubicin use is limited by cardiovascular toxicity, with cellular senescence proposed as a mechanism, and whether vildagliptin could reduce senescence and improve vascular smooth muscle relaxation was investigated.
Does vildagliptin improve vascular smooth muscle relaxation and reduce cellular senescence in doxorubicin-treated rats?
Does vildagliptin improve vascular smooth muscle relaxation and reduce cellular senescence in doxorubicin-treated rats?
Answers are grounded in this paper and cite their sources.
Vildagliptin and GLP-1 reduce cellular senescence and improve vascular smooth muscle relaxation in doxorubicin-induced cardiovascular toxicity models, suggesting potential for incretin-based drugs in this setting.
Doxorubicin (DOX) is a chemotherapeutic agent used in cancer treatment. Its use is limited by later toxicity to the cardiovascular system (CVS). Cellular senescence has been proposed as one mechanism of DOX toxicity. It has also been suggested that senescence reduction can improve the condition in many pathologies. We hypothesised that vildagliptin treatment can reduce senescence and thus improve the relaxation of vascular smooth muscle (VSM) in the aorta of a rat DOX model. The rats received DOX and were treated with vildagliptin for 6 weeks. Thereafter, the rats were sacrificed, and the aorta prepared for measurements of VSM relaxation and RNA isolation to detect the level of senescence markers. To further prove the antisenescence effect of the main vildagliptin effector glucagon-like peptide 1(GLP-1), VSM cells (VSMCs) were incubated with DOX and treated with GLP-1. Subsequently, senescence was detected by senescence-associated beta-galactosidase (SA-β-gal) and by the presence of senescence markers. DOX in rats caused diminished relaxation of VSM to sodium nitrate and caused an increase in the senescence mRNA markers p16Ink4a and p27Kip1 and the senescence-associated secretory phenotype (SASP) IL-6 and IL-8. Vildagliptin treatment led to improved relaxation and a reduction in senescence and SASP markers. Furthermore, in VSMCs DOX increased SA-β-gal activity, p16Ink4a, p27Kip1, IL-6 and IL-8, and GLP1 treatment led to a decrease of both senescence and SASP markers. In summary we conclude that vildagliptin can reduce senescence and improve relaxation of vascular smooth muscle in the aorta of DOX-treated rats, and GLP-1 can reduce senescence of DOX-treated VSMCs. These data suggest that incretin-based drugs are promising candidates for patients suffering from late doxorubicin cardiovascular toxicity.
No takes yet. Share an insight, caveat, or question.
Mišúth et al. (2021) studied Doxorubicin-induced cardiovascular toxicity. Vildagliptin vs. Doxorubicin alone was evaluated on Vascular smooth muscle relaxation and senescence markers. Vildagliptin treatment improved vascular smooth muscle relaxation and reduced senescence and SASP markers in the aorta of doxorubicin-treated rats.
Synapse has enriched 10 related papers. Consider them for comparative context: